First Trust Advisors LP Decreases Holdings in PTC Therapeutics, Inc. $PTCT

First Trust Advisors LP decreased its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 12.6% in the first quarter, Holdings Channel reports. The fund owned 136,003 shares of the biopharmaceutical company’s stock after selling 19,593 shares during the quarter. First Trust Advisors LP’s holdings in PTC Therapeutics were worth $9,266,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in PTC Therapeutics by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 8,803,203 shares of the biopharmaceutical company’s stock valued at $668,691,000 after purchasing an additional 514,204 shares during the period. Wellington Management Group LLP lifted its stake in shares of PTC Therapeutics by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company’s stock valued at $301,856,000 after purchasing an additional 224,481 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of PTC Therapeutics by 28.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock worth $368,587,000 after purchasing an additional 1,077,776 shares during the period. State Street Corp boosted its holdings in shares of PTC Therapeutics by 34.2% in the 4th quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock worth $319,497,000 after purchasing an additional 1,071,343 shares during the period. Finally, Toronto Dominion Bank increased its position in shares of PTC Therapeutics by 27.5% during the 4th quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock valued at $314,339,000 after purchasing an additional 891,690 shares during the last quarter.

PTC Therapeutics Stock Performance

Shares of NASDAQ PTCT opened at $68.01 on Friday. The business’s 50 day moving average price is $77.57 and its 200-day moving average price is $72.74. PTC Therapeutics, Inc. has a fifty-two week low of $43.17 and a fifty-two week high of $90.87. The company has a market cap of $5.64 billion, a price-to-earnings ratio of -117.26, a PEG ratio of 6.58 and a beta of 0.53.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.68. The company had revenue of $360.52 million during the quarter, compared to analysts’ expectations of $298.63 million. PTC Therapeutics had a negative return on equity of 362.45% and a negative net margin of 3.80%.PTC Therapeutics’s revenue was up 101.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.83) EPS. Sell-side analysts predict that PTC Therapeutics, Inc. will post 0.41 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on PTCT shares. Zacks Research upgraded PTC Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 7th. Morgan Stanley lifted their price objective on shares of PTC Therapeutics from $93.00 to $104.00 and gave the stock an “overweight” rating in a research note on Friday. Wall Street Zen upgraded shares of PTC Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Jefferies Financial Group raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating and increased their target price for the company from $76.00 to $85.00 in a research note on Wednesday, May 27th. Finally, Raymond James Financial initiated coverage on shares of PTC Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $108.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $95.75.

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported second-quarter revenue of approximately $361 million, including $239 million in product revenue, up 101.5% year over year. Adjusted earnings of $0.92 per share exceeded consensus expectations, while the company moved from a year-ago loss to a profit. PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Sephience (sepiapterin) generated $151 million in second-quarter revenue, with management citing continued broad adoption and international expansion. This performance supports the drug’s role as a key commercial growth driver. Corporate Update and Financial Results
• Positive Sentiment: The company raised its full-year 2026 outlook, projecting total revenue of $1.18 billion to $1.28 billion and product revenue of $850 million to $950 million. PTC also reported a substantial cash balance of $2.2 billion at June 30, providing financial flexibility. Corporate Update and Financial Results
• Neutral Sentiment: The earnings call and follow-up analysis frame PTC Therapeutics as entering a strategically important phase, with investors focused on Sephience’s continued launch trajectory, additional pipeline opportunities and execution against the updated financial targets. PTC Therapeutics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the headline beat and raised guidance, the stock’s reaction suggests investors may have been expecting even stronger results or a more aggressive outlook. PTC remains unprofitable on a reported basis, with a negative net margin, leaving valuation sensitive to sustained commercial growth and pipeline execution. PTC Therapeutics Q2 Key Metrics Versus Estimates

Insider Transactions at PTC Therapeutics

In other news, VP Mark Elliott Boulding sold 5,079 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $85.08, for a total value of $432,121.32. Following the transaction, the vice president directly owned 105,272 shares in the company, valued at approximately $8,956,541.76. This represents a 4.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mary L. Smith sold 15,834 shares of the firm’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $90.00, for a total transaction of $1,425,060.00. Following the completion of the transaction, the director directly owned 21,813 shares in the company, valued at $1,963,170. This represents a 42.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 198,662 shares of company stock worth $16,347,994. 5.50% of the stock is currently owned by insiders.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.